Online Investor Kit

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

Date Documents

Recent SEC Filings

Filing date Form Description Filing Group Downloads
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
8-K

Report of unscheduled material events or corporate event

Current Reports

Fact Sheets

There are currently no items available.

Recent Press Releases

Date Title and Summary
Toggle Summary Pacira Receives European Commission Approval for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain
--Approval based on four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery-- --EXPAREL is the first long-acting non-opioid option for field block and brachial plexus or femoral nerve block approved in Europe -- PARSIPPANY, N.J. , Nov.
Toggle Summary Pacira BioSciences Reports Preliminary Net Product Sales of $41.7 Million for October 2020
-- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 -- PARSIPPANY, N.J. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net
Toggle Summary Pacira BioSciences to Present at the 2020 Jefferies Virtual London Healthcare Conference
PARSIPPANY, N.J. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacira   BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Jefferies Virtual London Healthcare Conference at 2:05 PM GMT ( 9:05 AM ET ) on Tuesday, November 17, 2020 .
Toggle Summary Pacira BioSciences Reports Third Quarter 2020 Financial Results and Business Update
-- EXPAREL average daily sales at 110% of the prior year for the third quarter-- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today
Toggle Summary Pacira Launches State-of-the-Art Training Center Dedicated to Advancing Best Practice Regional Approaches to Manage Acute Pain
-- The Pacira Innovation and Training Center of Tampa will provide clinicians with a flexible environment for hands-on learning-- PARSIPPANY, N.J. , and TAMPA, Fla. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NADSAQ: PCRX), the leading provider of non-opioid pain management
Toggle Summary Pacira to Report Third Quarter 2020 Financial Results on Thursday October 29, 2020
PARSIPPANY, N.J. , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday, October 29, 2020 . Following the release, the company will host a live conference call
Toggle Summary Pacira BioSciences Reports Preliminary Net Product Sales of $116.9 Million for the Third Quarter of 2020
-- EXPAREL average daily sales at 110% of the prior year for the third quarter and 110% of the prior year for the month of September -- PARSIPPANY, N.J. , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management
Toggle Summary Pacira Receives Positive CHMP Opinion for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain
-- CHMP opinion supported by four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery -- -- European Commission decision on the Marketing Authorization Application (MAA) expected in November 2020 -- PARSIPPANY, N.J. , Sept.
Toggle Summary IPG and Pacira BioSciences Announce Collaboration to Reduce Postsurgical Opioid Prescribing and Surgical Procedure Costs
ALPHARETTA, Ga. and PARSIPPANY, N.J. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- IPG, the industry-leading provider of surgical cost management solutions, and Pacira BioSciences, Inc. (NADSAQ: PCRX), a leading provider of non-opioid pain management options, today announced a collaboration to reduce
Toggle Summary Pacira BioSciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference
PARSIPPANY, N.J. , Sept. 11, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 H.C. Wainwright 22 nd Annual Global Investment Conference at 3:30 PM ET on Monday, September 14, 2020 . Live audio of the virtual event can be accessed by